{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:08:17Z","timestamp":1791900497442,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T00:00:00Z","timestamp":1127174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Clinical correlates and long\u2010term prognostic relevance of the <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup> mutation was studied in 150 patients with essential thrombocythaemia (ET) from a single institution and followed for a median of 11\u00b74\u2003years. During this period, thrombotic complications were documented in 62 patients (41\u00b73%) and transformation into acute myeloid leukaemia (AML), polycythaemia vera (PV), or myelofibrosis with myeloid metaplasia (MMM) occurred in 4 (2\u00b77%), 8 (5\u00b73%), and 15 (10%) patients, respectively. <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup> was detected in either archived bone marrow or blood cells from 73 patients (48\u00b77%) but none were homozygous for the mutant allele. Parameters at diagnosis that were significantly associated with the presence of <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup> included advanced age and higher counts of both haemoglobin and leucocytes. During follow\u2010up, patients with the mutation were more likely to transform into PV but the incidences of AML, MMM, or thrombotic events were similar between patients with and without the mutation. Multivariate analysis identified advanced age, higher haemoglobin level, and thrombosis history but not the presence of <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup> as independent predictors of inferior survival. Therefore, although the presence of <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup> in ET appears to promote a PV phenotype, it might not carry treatment\u2010relevant information.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05764.x","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T08:23:15Z","timestamp":1127204595000},"page":"208-213","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":247,"title":["<i>JAK2<\/i><sup>V617F<\/sup> mutation in essential thrombocythaemia: clinical associations and long\u2010term prognostic relevance"],"prefix":"10.1111","volume":"131","author":[{"given":"Alexandra P.","family":"Wolanskyj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gary Gilliland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","article-title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG\u2010rHu MGDF) in essential thrombocythaemia","volume":"96","author":"Axelrad A.A.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_3_1","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow P.J.","year":"1981","journal-title":"Blood"},{"key":"e_1_2_5_7_1","article-title":"The Jak2V617F mutation, PRV\u20101 overexpression and EEC formation define a similar cohort of MPD patients","author":"Goerttler P.S.","year":"2005","journal-title":"Blood First Edition Paper"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05543.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01667.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.2.417"},{"key":"e_1_2_5_11_1","volume-title":"WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_5_13_1","article-title":"JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia\u2010chromosome negative CML and megakaryocytic leukemia","author":"Jelinek J.","year":"2005","journal-title":"Blood First Edition Paper"},{"key":"e_1_2_5_14_1","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","author":"Jones A.V.","year":"2005","journal-title":"Blood First Edition Paper"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08271.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05149.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03386.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982575"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05098.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2341"},{"key":"e_1_2_5_24_1","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u2018atypical\u2019 myeloproliferative disorders and the myelodysplastic syndrome","author":"Steensma D.P.","year":"2005","journal-title":"Blood First Edition Paper"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.22"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3505"},{"key":"e_1_2_5_27_1","first-page":"871","article-title":"FIP1L1\u2010PDGFRA and c\u2010kit D816V mutation\u2010based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi A.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05743.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90235.x"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05764.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05764.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:17:24Z","timestamp":1697419044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05764.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,30]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05764.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05764.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,30]]},"assertion":[{"value":"2005-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}